Background. The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4 + cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIVinfected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype.
1 ϫ 10 1 ϫ 10 significant association between HCV RNA load and achievement of an increased CD4 + cell count (adjusted RH, 0.97; 95% CI,  ). There was no clear association between HCV genotype and the probability of P p .83 achieving a CD4 + cell count increase. Conclusions. An association between the presence of HCV-Ab and immune reconstitution after HAART has been shown elsewhere. Results of our large, prospective study support a direct role of HCV viremia in the CD4 + cell count response to HAART. Moreover, our results underline the fact that, in individuals coinfected with HIV and HCV, the goal of treating HCV infection is to eradicate HCV, to both slow the rate of HCV progression and limit potential interference with the response to HAART.
Prospective studies have reported that HIV-infected subjects who test positive for hepatitis C virus (HCV) Improving our knowledge about the effects of HCV viremia and HCV genotype in HIV-infected patients receiving HAART may be useful to better understand the interaction between these 2 viruses and to optimize the timing of antiviral therapies in coinfected patients. In the present analysis, we evaluated whether the CD4 + cell count response to HAART in patients with HCV viremia was different from the response in HCVAb-negative patients using data from the Italian Cohort Naive for Antiretrovirals (I.Co.N.A.), which includes persons who were antiretroviral naive at the time of enrollment. We also aimed to assess whether the response to HAART varied according to HCV RNA load or HCV genotype. In a previous analysis of patients included in the I.Co.N.A. cohort, the CD4 + cell count response to HAART in subjects with serological evidence of HCV infection was impaired, compared with the response in HCV-Ab-negative subjects [3] .
PATIENTS AND METHODS
Study population. I.Co.N.A. is an Italian, multicenter, prospective, observational study cohort started in 1997 that includes HIV-infected adults who were antiretroviral naive at the time of enrollment. Demographic characteristics, clinical and laboratory values, and treatment history are recorded at enrollment and at intervals of at least 6 months thereafter. Plasma samples are prospectively collected and stored on a voluntary basis by participating centers [10] . The present study involves subjects from I.Co.N.A. who were antiretroviral naive before I.Co.N.A. enrollment and received a HAART regimen of у3 drugs after enrollment, who were tested for HCV-Ab and were negative for hepatitis B virus surface antigen during the 6-month period before starting HAART, who had at least 1 CD4 + cell count measurement and 1 HIV RNA measurement during the 6-month period before starting HAART, who had at least 1 CD4 + cell count measurement after at least 1 week of HAART, and who, if HCV-Ab positive, had at least 1 plasma sample stored during the 6-month period before starting HAART to distinguish between those who were and those were not HCV viremic (HCV RNA loads 15 and р5 IU/mL, respectively) and to assess HCV genotype. Subjects treated at any time with IFN or other immunomodulating agents were excluded from the study.
Laboratory testing. Plasma samples were stored at Ϫ80ЊC, and the HCV RNA load was measured with Versant HCV RNA Ultrasensitive, version 3.0 (Bayer Diagnostics). If HCV RNA levels were less than the lower limit of quantification (521 IU/ mL), HCV viremia was determined by a qualitative test that was based on a transcription-mediated assay (TMA; Bayer Diagnostics) with a sensitivity of 5 IU/mL. HCV genotype was assessed in HCV RNA-positive samples by the reverse hybridization method (InnoLipa HCV II; Bayer Diagnostics); in subjects with HCV RNA levels of 5-521 IU/mL, TMA amplicons were used as starting materials for PCR before reverse hybridization was performed. HCV-Ab seropositivity was confirmed in stored plasma specimens by a third-generation immunoassay (Axsym HCV, version 3.0; Abbott Laboratories).
Statistical analysis. To test whether HCV-Ab-positive patients for whom a stored plasma specimen was available were systematically different from those for whom no sample was available, we compared the baseline demographic and clinical characteristics of these 2 groups using the x 2 test (for categorical variables) and Wilcoxon's test (for continuous variables) for independent samples. Patients were characterized as HCV-Ab negative or HCV viremic. In turn, we grouped HCV-viremic patients according to HCV genotype (genotypes [1] [2] [3] [4] and HCV RNA load (with a cutoff of IU/mL, the approximate 6 1 ϫ 10 median HIV RNA load among viremic subjects). Subjects in these groups were compared with respect to demographic, clinical, and therapeutic characteristics using the x 2 test. Median age at enrollment, HIV RNA and HCV RNA loads, serum alanine aminotransferase (ALT) level, and CD4
+ cell count at the time of HAART initiation were compared between groups using the Kruskall-Wallis test. HIV RNA and HCV RNA levels were measured on a log 10 scale. For HCV RNA or HIV RNA loads less (or greater) than the lower (or upper) limit of detection, we simply imputed the logarithm of the lower (or upper) detection limit.
The end point of the analysis was the CD4 + cell count response to HAART. This was defined as the time required to initially achieve a specified CD4 + cell count increase (у100, у200, and у300 cells/mL) from pre-HAART levels after starting HAART. Follow-up immunological data for individual patients were truncated at the first date on which virological failure was observed (i.e., the date on which the first of 2 consecutive HIV load measurements 1500 copies/mL was recorded), and analyses were performed according to an intention-to-treat principle (i.e., treatment modifications were ignored). We also performed a "during treatment" analysis by censoring follow-up data at the time of discontinuation of у1 of the drugs contained in the original HAART regimen. A standard multivariable Cox regression analysis was used, and the relative hazard (RH) of achieving a CD4 + cell count response was determined for subjects with a HCV RNA load 1 IU/mL (high HCV RNA 6 1 ϫ 10 load), subjects with a HCV RNA load of 5-IU/mL (low 6 1 ϫ 10 HCV RNA load), and subjects who were HCV-Ab negative. In HCV-viremic subjects for whom the HCV genotype could also be assessed, the time required to achieve the end points defined above was compared on the basis of HCV genotype.
RESULTS
Of the 5843 subjects enrolled as of 10 May 2004 in I.Co.N.A., 2910 ) initiated HAART as their first antiretroviral regimen; 2071 (71.2%) of these 2910 met the inclusion criteria. Median interval between plasma sample collection and HAART initiation, weeks (IQR) … 1 (0-6) 2 (0-9) 2 (0-9) .52 Median duration of immunological follow-up, weeks (range) 33 45 42 36 .003
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; IQR, interquartile range; NNRTI, nonnucleoside-analogue reverse-transcriptase inhibitor; NRTI, nucleoside-analogue reverse-transcriptase inhibitor; PI, protease inhibitor; SQV HG, hard-gel formulation of saquinavir.
A total of 1219 (58.9%) of the 2071 patients were HCV-Ab negative, 527 (25.4%) were HCV-Ab positive and had no stored plasma specimen, and 325 (61.7%) were HCV-Ab positive and had a plasma sample obtained and stored a median of 2 weeks before HAART initiation. There were no significant differences between the baseline characteristics of these 325 patients and those of the 527 HCV-Ab-positive subjects who did not have a stored plasma specimen (data not shown). We found that 41 (12.6%) of 325 subjects had a HCV RNA load !5 IU/mL. These patients were excluded from the analysis, because our aim was to restrict the comparison to HCV-Ab-negative patients and HCV-viremic patients.
The characteristics of the 1503 subjects included in the analysis (1219 HCV-Ab-negative patients and 284 HCV-viremic patients grouped according to HCV RNA load) are summarized in table 1. HCV-Ab-negative participants were significantly more likely to be female ( ). Conversely, they were less P p .05 likely to be injection drug users ( ) and to have started P ! .001 treatment with the hard-gel formulation of saquinavir as a single PI ( ). ALT levels were significantly higher in HCV-P ! .001 viremic patients, compared with HCV-Ab-negative patients ( ). At HAART initiation, HCV-Ab-negative patients P ! .001 seemed to have higher HIV RNA levels than did HCV-viremic patients (0.2 log 10 difference;
), but the result may P p .0001 not be clinically significant, because the measurement error of the viral load assays we used can be as high as 0.17 log 10 IU/ mL [11, 12] .
In the 284 HCV-viremic subjects, the median pre-HAART HCV RNA load was 6.09 log 10 + cell count increase of у100 cells/mL from the pre-HAART level for patients who tested negative for hepatitis C virus (HCV) antibody (solid line), patients who had low levels of HCV RNA replication (short-dashed line), and patients who had high levels of HCV RNA replication (long-dashed line). Numbers of patients still at risk at various time points after the initiation of HAART are shown at the bottom. Log-rank analysis of the difference between groups revealed that . P p .0001
for patients with HCV genotype 1 (44 U/L) and patients with HCV genotype 4 (47 U/L) ( ). P p .01
HCV Viremia Analysis
Time required to achieve a CD4 + cell count increase of у100 cells/mL from pre-HAART levels. A total of 1258 patients (83.7%) achieved an increase of у100 CD4 + cells/mL after starting HAART. The median time required to achieve this CD4 + cell count response was 23.1 weeks (95% CI, 22.0-24.1 weeks) for HCV-Ab negative patients, 29.3 weeks (95% CI, 24.1-43.1 weeks) for patients with a HCV RNA load of 5-copies/ 6 1 ϫ 10 mL, and 28.1 weeks (95% CI, 24.6-38.9 weeks) for patients with a HCV RNA load 1 copies/mL ( figure 1) . The log- 6 1 ϫ 10 rank test revealed a statistically significant difference between the 3 groups ( ), possibly signaling a difference be-P p .0001 tween the 2 curves for the HCV-viremic individuals and the curve for the HCV-Ab-negative individuals. In fact, when patients with low HCV RNA loads were used as the reference group in a comparison of patients with high and patients with low HCV RNA loads, the results of a multivariable Cox proportional hazards model revealed no evidence of a difference in the RH of achieving our definition of a CD4 + cell count response (adjusted RH, 0.97; 95% CI, 0.75-1.27;
). In P p .83 light of this finding, we introduced a binary covariate comparing HCV-viremic patients with HCV-Ab-negative patients in the final multivariable proportional hazards model. The results of this model are shown in table 2; age, previous diagnosis of AIDS, pre-HAART CD4 + cell count, and HIV RNA load were independently associated with the chance of achieving a CD4 + cell count increase of у100 cells/mL. Most importantly, the chance of achieving this end point appeared to be less for HCV-viremic patients than it was for patients with negative results of HCV-Ab tests (adjusted RH, 0.82; 95% CI, 0.66-1.01;
). Results were similar after adjusting for each specific P p .06 drug included in the original HAART regimen and for a timedependent covariate indicating the change in virus load from pre-HAART levels (data not shown). Furthermore, when the analysis was repeated after censoring follow-up data at the time of discontinuation of у1 of the drugs included in the original regimen, results were again similar (data not shown). In addition, for a given HCV RNA load, injection drug users were less likely than other patients to achieve a CD4 + cell count increase, but the difference was not statistically significant (adjusted RH, 0.86; 95% CI, 0.69-1.06;
). P p .15 Sensitivity analyses. A multivariable Cox regression model revealed that HCV viremia, rather than HCV-Ab negativity, tended to be associated with the time required to achieve an increase of у200 cells/mL in the CD4 + cell count (adjusted RH, 0.82; 95% CI, 0.64-1.06;
). Moreover, HCV viremia, P p .12 rather than HCV-Ab negativity, was significantly associated with the time required to achieve an increase of у300 cells/mL (adjusted RH, 0.69; 95% CI, 0.52-0.92; ). P p .01
HCV Genotype Analysis
Time required to achieve a CD4 + cell count increase of у100 cells/mL from pre-HAART levels. After excluding subjects with HCV genotype 2 because of their low number, we repeated the analyses for the remaining 277 subjects for whom the HCV genotype was known. Results of the log-rank test revealed no evidence of a genotype-based difference associated with achieving an increase of у100 cells/mL from the pre-therapy CD4 + cell count ( ) ( figure 2) . Overall, results of multivariable P p .81 analyses were inconclusive regarding differences in the chance of achieving a CD4 + cell count reconstitution to a level of у100 cells/mL above pre-HAART levels between patients with HCV genotype 1 and patients with either HCV genotype 3 (adjusted RH, 1.08; 95% CI, 0.81-1.47; ) or HCV genotype 4 P p .60 (adjusted RH, 0.90; 95% CI,  ) (table 3) . P p .59 Sensitivity analyses. Patients with HCV genotype 3 had a significantly reduced chance of achieving a CD4 + cell count increase of у300 cells/mL, compared with patients with HCV genotype 1 (adjusted RH, 0.61; 95% CI, 0.40-0.93; ). P p .02 However, this association was not confirmed in the analysis of the time required to achieve an increase of у200 CD4 + cells/ mL (adjusted RH, 0.84; 95% CI,  ). In con-P p .30 trast, no significant differences in the chance of achieving an increase of у200 cells/mL (adjusted RH, 0.89; 95% CI, 0.55-1.45; ) or у300 CD4 + cells/mL (adjusted RH, 0.85; 95% P p .64 CI, 0.55-1.31;
) were observed in patients with HCV P p .45 genotype 4.
DISCUSSION
In this cohort of antiretroviral-naive, HIV-infected subjects, we prospectively investigated the effect of plasma HCV viremia and HCV genotype on the CD4 + cell count response after initiation of HAART. After eliminating the possibility that HCVAb-positive patients were misclassified as HCV infected and adjusting for potential confounders, we found that the chance of achieving a CD4 + cell count increase of у100 cells/mL for HCV-viremic patients was 18% less than the chance for HCVAb-negative patients, although results of Kaplan-Meier analysis suggest that the effect of HCV infection on CD4 + cell count response may be negligible. This difference was not statistically + cell count increase of у100 cells/mL from pre-HAART level for patients with hepatitis C virus (HCV) genotype 1 (solid line), HCV genotype 3 (short-dashed line), and HCV genotype 4 (long-dashed line). Numbers of patients still at risk at various time points after the initiation of HAART are shown at the bottom. Log-rank analysis of the difference between groups revealed that . P p .81 Table 3 . Cox proportional hazards model of the relative hazard (RH) of achieving a CD4 + cell count increase of у100 cells/mL from pre-HAART levels, according to hepatitis C virus (HCV) genotype. a Adjusted for pre-HAART HIV RNA load, pre-HAART CD4 + cell count, mode of HIV transmission, sex, age, previous AIDS diagnosis, pre-HAART alanine aminotransferase level, type of HAART, and the hard-gel formulation of saquinavir as the only protease inhibitor received.
significant at the conventional a of .05 ( ), but similar P p .06 effects were observed in sensitivity analyses using alternative end points. In particular, for HCV-viremic patients, the adjusted RH of achieving a CD4 + cell count increase of у300 cells/mL was significantly reduced by 31% after initiation of HAART ( ). Nevertheless, this effect does not seem to P p .01 be related to different HCV RNA loads. Interestingly, our analysis suggests that HCV viremia was a stronger predictor of a poorer CD4 + cell count response than was injection drug use. Our results are consistent with those of previous prospective studies in which an impairment of the immune response to HAART associated with HCV infection was reported. However, all of these studies defined HCV infection on the basis of the presence of HCV-Ab and therefore potentially included HCVnonviremic patients in the group of HCV-infected patients [1, 2] . Specifically, because 5%-10% of HCV-Ab-positive, HIVcoinfected individuals naturally clear the infection [13] , a definition of HCV infection that is based on the presence of HCVAb could lead to a misclassification of such patients.
One retrospective study comparing the immunological response to HAART after 1 year of therapy in HCV RNApositive patients with the response in HCV RNA-negative patients did not find any relationship between HCV RNA positivity and the overall mean increase in the CD4 + cell count [14] . Differences in the study designs and in the clinical and demographic characteristics of the study populations might explain these inconsistencies.
The mechanisms by which HCV may alter immune recovery after HAART, irrespective of the amount of circulating virus, can only be speculated. HCV is essentially an hepatotropic virus, but it may be also lymphotropic [15] [16] [17] [18] [19] . Moreover, the presence of the HCV RNA-negative strand in CD4 + cells as well as in lymph nodes of coinfected patients suggests that HCV may actively replicate in the same T cells as HIV [19, 20] . The recent in vitro observation that HCV infection of native human monocytes-macrophages may be facilitated by HIV also supports the hypothesis of a negative effect of HCV on the kinetics of T cells-especially CD4
+ cells-in HIV-infected patients [21, 22] .
In our study, the CD4 + cell count response to HAART was similar for all patients with a HCV RNA load у5 IU/mL. Although data from simultaneous measurements of plasma HCV RNA load and HCV replication in T cells are lacking in our study, some studies involving in vivo and in vitro analyses suggest that HCV replicates slowly into lymphocytes and that the rate of HCV replication may be independent of the plasma HCV levels [16, 23] ; the rate of HCV replication in T cells is generally very low [19, 24] , and different ratios of positive strands to negative strands of HCV RNA between hepatocytes and monocytes-macrophages have been detected [25] .
We also analyzed the association between HCV genotype and the CD4 + cell count response to HAART. Recently, in a population of young, hemophiliac, antiretroviral-naive, HIVinfected patients, coinfection with HCV genotype 1 was associated with faster progression to HIV disease than was coinfection with other HCV genotypes [8] . In our analysis, patients infected with HCV genotype 3 seemed to have a slower immune recovery than patients infected with HCV genotype 1, but we found inconsistent results overall. However, a real difference between HCV genotype and the CD4 + cell count response to HAART may exist, but it could not be detected by our test, because of the small sample size and/or the short follow-up period. Our data are consistent with those of a previous report showing that coinfected subjects with well-controlled HIV replication and a CD4 + cell count increase of !50 cells/mL during HAART frequently harbored HCV genotype 3a [2] . Moreover, HCV genotype 3 has been related to hepatic steatosis [26, 27] , increased ALT level, and the risk for developing a severely increased ALT level after HAART [28] . Therefore, an association between HCV genotype 3 and an impaired CD4 + cell count response to HAART would be an important finding, because current HCV treatment seems to be more effective against HCV genotype 3 [29] .
Our study has some possible limitations. Measurement of the HCV RNA load was performed only for HCV-Ab-positive patients for whom stored plasma specimens were available. However, we have shown that baseline demographic and clinical characteristics for this group of patients were similar to those for HCV-Ab-positive subjects for whom no stored plasma specimens were available. Similarly, it is unlikely that frozen storage and thawing could have substantially affected the results of this analysis [30] . Samples obtained from persons enrolled in the I.Co.N.A. are frozen within hours after collection, and virological tests were performed on aliquots that had not previously been thawed. We measured the pre-HAART HCV RNA load only once, and we could have misclassified subjects who had fluctuating HCV RNA loads. However, no significant changes in HCV RNA levels were observed over time in patients coinfected with HIV and HCV [31] . Also, a false-negative result of a HCV-Ab test could have led to a misclassification of some subjects. However, in populations at high risk for HCV infection, such as HIV-infected patients, the probability of falsenegative results of anti-HCV immunoassays is negligible [32] . Because it was not possible to reasonably distinguish between active and nonactive injection drug users in the I.Co.N.A., we cannot rule out the presence of residual confounding. Moreover, our analysis lacks adjustment for adherence to therapy. Because adherence is strongly associated with a better virological response to HAART and because coinfected patients have a higher rate of therapy discontinuation [33, 34] , confounding cannot be ruled out. Finally, because enrollment in the cohort started in 1997, a proportion of subjects have been treated with HAART regimens that are considered to be suboptimal according to current standards. However, we included this factor in the multivariable analysis.
Overall, data from this large, prospective study confirm that HCV infection seems to be associated with an impaired CD4 + cell count response to HAART. To our knowledge, this is the first prospective study that extends this finding to a HCVviremic population. In the light of our results, the treatment of hepatitis C in patients coinfected with HIV and HCV could not only potentially eradicate HCV, but it could also reduce the possible interference of hepatitis C in a patient's response to HAART. Moreover, among coinfected persons for whom antiretroviral therapy may be safely deferred, treatment for HCV infection should be considered appropriate regardless of the extent of HCV-associated hepatic damage and may precede initiation of HAART. 
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